Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna

Vertex Pharmaceuticals

Eli Lilly could have the world's future best-selling drug in its lineup. Moderna is poised to expand beyond COVID with several new products potentially on the way.

3 Magnificent Growth Stocks to Buy in March

Eli Lilly dominated 2023 thanks in large part to Mounjaro, its flagship diabetes medication. The pharma giant also has multibillion-dollar drugs in cancer, plaque psoriasis, and more.

Is It Too Late to Buy Eli Lilly Stock Now?

Lilly's new weight-loss drug could top $62 billion in 2030 sales, an analyst said Friday as he boosted his price target on Eli Lilly stock to 1,000.

Eli Lilly Stock And The Road To 1,000: Weight-Loss Drugs Could Generate $81 Billion

Adobe

MongoDB

One of the most exciting things for an investor or trader is to look at tier account statement, or at the charts of what they own, and see a stock like Nvidia Corp. NASDAQ: NVDA or even the broader SPDR S&P 500 ETF Trust NYSEARCA: SPY or Invesco QQQ NASDAQ: QQQ rallying to new highs.

3 Stocks Showing Constructive Pullbacks with Indexes at New Highs

Transmedics Group Inc

Verona Pharma

Eli Lilly has been one of the hottest names in healthcare thanks to its anti-obesity and diabetes treatments. TransMedics has been more than doubling sales and expects around 50% revenue growth this year.

3 Healthcare Stocks That Have Outperformed Nvidia Since 2022

Intuitive Surgical

Novo Nordisk

The Magnificent Seven are stealing the show this year on the market. They're all technology companies -- but there are opportunities elsewhere, too.

These 4 Stocks Are the "Magnificent Seven" of Healthcare

Vertex, Eli Lilly, and Novo Nordisk have many of the traits of the "Magnificent Seven." All three biotech stocks should continue delivering outsized returns for a long time.

Could These 3 Companies Headline a "Magnificent Seven" of Biotech Stocks?

Chipotle

NVIDIA

While stock splits don't necessarily change the valuation of a company's stock. They do offer some benefits.

Stock Splits Watch: 3 Likely Candidates to Keep on Your Radar in 2024

Ralph Lauren

Uber

As March 2024 draws near, the performance of the S&P 500 Index is starting to reveal itself, with some stocks demonstrating notable growth while others show potential for valuation increases in the months ahead.

Best performing S&P 500 stocks in 2024

Eli Lilly 's CEO David Ricks told Reuters on Wednesday that the U.S. drugmaker expects to launch its obesity drug in Indian market as early as next year.

Exclusive: Lilly CEO says its obesity drug could enter India as early as 2025

A rival's weight-loss drug candidate did well in a mid-stage clinical trial. The treatment met all of its endpoints in the study.

Why Novo Nordisk and Eli Lilly Stocks Slipped Today

Broadcom

Tesla

CNBC's Jim Cramer on Monday Eli Lilly, Berkshire Hathaway, Tesla and Broadcom have a chance to break the $1 trillion market cap barrier.

Cramer names contenders for the next company to hit $1 trillion market cap

LVMH Moet Hennessy Louis Vuitton

Taiwan Semiconductor Manufacturing

Investors learned an important lesson in 2023: investing in the biggest companies and their stocks is a surefire way to capture strong gains. The Magnificent 7 – all of which are trillion dollar stocks – produced strong returns for investors.

Future Juggernauts: The Next 7 Trillion Dollar Companies to Buy Now

Merck

Vericel

Pharma stocks and massive potential are synonymous. With horrible diseases like cancer, diabetes, and heart disease still a mile away from developing a cure, drugs that address these conditions command outrageous prices.

3 Top Pharma Stocks for Investors Betting on a Biotech Boom

Zealand Pharma's Phase 2 trial was an "uniquivocal win" for a drug that can treat both liver disease and obesity, analysts said.

Novo Nordisk and Eli Lilly rival soars 26% after promising weight-loss drug results

Eli Lilly's medicines Zepbound and Mounjaro are seeing wild demand. The party isn't going to stop anytime soon.

Is Eli Lilly Stock Going to $950? 1 Wall Street Analyst Thinks So.

AbbVie

Gilead Sciences

AbbVie is a Dividend King that's poised to soon return to robust growth. Eli Lilly's dividend is growing rapidly but is overshadowed by its tremendous stock gains.

3 Dividend Stocks That Are No-Brainer Buys Right Now

There's a growing field of competitors in the weight-loss drugs space, where Lilly and Novo currently dominate. Is Eli Lilly stock a buy?

Is Eli Lilly Stock A Buy As Amgen Enters The Red-Hot Weight-Loss Ring?

Eli Lilly's sales and profits are likely to be boosted by new treatments for diabetes, weight loss, and potentially Alzheimer's. The stock's valuation is pricey, but it could look cheap years from now as the business gets bigger.

Could Eli Lilly Stock Help You Become a Millionaire?

Applied Materials

General Electric

Howmet Aerospace

Netflix

Stryker

Large growth stocks are dominating this year. But some investors are cashing in even faster in by finding the best-of-the-best growth S&P 500 stocks.

Investors Cash In Fast On 10 Large Stocks With Insane Momentum

Eli Lilly is a large force in the diabetes and obesity care markets. Its cancer drug, Verzenio, just received an expanded indication from the FDA.

Here's 1 Pharmaceutical Stock That Looks Unstoppable. Hint: It's Not Novo Nordisk.

An analyst downgraded the pharmaceutical mainstay's shares. He now feels the company is only a hold; previously, he tagged it as worthy of a buy.

Why Eli Lilly Stock Was Feeling Sickly on Wednesday

Advanced Micro Devices

Microsoft

Spotify

Walmart

Analysts love growth stocks, especially those that continue to register strong earnings growth and dominate the markets in which they compete. In fact, I discuss a few of them below.

Wall Street Favorites: 7 Growth Stocks With Strong Buy Ratings for February 2024

Visa

The Magnificent 7 stocks were one of the biggest stories in markets in 2023. They were responsible for an outsized share of market returns, proving the incredible value of tech to the overall economy.

3 Stocks With the Potential to Knock Tesla Out of the Magnificent 7

Eli Lilly is enjoying impressive revenue growth fueled by high demand for its diabetes treatments. However, the company also develops medications for cancer, plaque psoriasis, and obesity.

News for Eli Lilly Stock (LLY)